TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05265663

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic ablative radiotherapy
Description: SABR will be delivered in an image-guided hypofractionated scheme of 5 fractions of 8 Gy (total 40 Gy), prescribed to 95% of the planning target volume (PTV). Treatment is delivered on alternate days within a maximum overall treatment duration of 14 days.
Study: NCT01471132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 345mg/m2,43℃，30mins

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 260mg/m2,43℃，30mins
Study: NCT03950180

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prostate Cancer Comorbidity Index (PCCI) score
Description: Life expectancy information
Study: NCT03381001

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: embryo transfer after thaw and culture
Description: embryos will be kept in culture after thawing for one day before transfer for the uterus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: embryo transfer with no culture
Description: embryos will be transfer with no culture after thaw
Study: NCT03712735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.08% - fentanyl 2mcg
Description: In each arm, bupivacaine and fentanyl are being delivered at different intervals and rates for the maintenance of labor analgesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.08% - fentanyl 2mcg
Description: In each arm, bupivacaine and fentanyl are being delivered at different intervals and rates for the maintenance of labor analgesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.08% - fentanyl 2mcg
Description: In each arm, bupivacaine and fentanyl are being delivered at different intervals and rates for the maintenance of labor analgesia.
Study: NCT01782742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexarotene
Description: Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01953003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinflunine
Description: intravenous administration day 1 once every 3 weeks, 280 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Arm A : 1650 mg/m² Arm B : 2500 mg/m²

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Arm A : 1650 mg/m² Arm B : 2500 mg/m²
Study: NCT04495439

Intervention type: DEVICE
Group type: OTHER
Intervention: Augmentation with the ISS Study System
Description: Augmentation with the ISS Study System

Intervention type: OTHER
Group type: OTHER
Intervention: Augmentation with PMMA
Description: Augmentation with PMMA (standard)
Study: NCT01043016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: patient undergo Photocyanine Injection via venous infusion followed by photodynamic therapy with 670nm diobe laser 24 hours later
Study: NCT02512679

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide Dose Level 1
Description: given by IV at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level. After ten patients the de-escalation will begin if the stopping rule is not met.

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide Dose Level 2
Description: Level 2 will be 70mg/kg in 2 divided given once a day for 2 days;

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide Dose Level 3
Description: Level 3 will be 35mg/kg as a one-time dose.

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide Dose Level 4
Description: Level 4 will be no cytoxan.
Study: NCT02098408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Description: Neurocognition will be trained using the NEAR model (Medalia et al. 2003), whereas the training of social cognitive skills will be by use of the SCIT manual (Social Cognition and Interaction Training) developed by Roberts et al. 2014.~The intervention consists of 24 group sessions taking place once a week (two hours) and additional neurocognitive training at home. Furthermore, there will be a total of 12 individual sessions aiming at bridging the cognitive training to the everyday functioning of the patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Patients allocated to the control condition are free to choose whatever standard treatment they are offered by the clinicians managing their treatment. Usually standard treatment consists of regular contact to health professionals in the in- and outpatient facilities in Copenhagen, Denmark, and encompass different kinds of supportive counselling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Patients allocated to the control condition are free to choose whatever standard treatment they are offered by the clinicians managing their treatment. Usually standard treatment consists of regular contact to health professionals in the in- and outpatient facilities in Copenhagen, Denmark, and encompass different kinds of supportive counselling.
Study: NCT04959630

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinical decision making based on visualizing liver 3D models in Virtual Reality (VR) environment or via a Desktop Interface (DI)
Description: Visualizing 3D models of livers for preoperative surgical planning via two different environment: DI and VR in sequential order

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinical decision making based on visualizing liver 3D models in Virtual Reality (VR) environment or via a Desktop Interface (DI)
Description: Visualizing 3D models of livers for preoperative surgical planning via two different environment: DI and VR in sequential order
Study: NCT02803437

Intervention type: DRUG
Intervention: Radium-223 dichloride (Xofigo, BAY 88-8223)
Description: Xofigo treatment will be performed according to the product label in Japan under the routine clinical practice.
Study: NCT02675478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Study: NCT01255592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: Oral dose bid
Study: NCT03489707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based human papillomavirus (HPV) DNA screening
Description: Persons randomized to arm 1 will receive an HPV DNA home-based collection kit in the mail at 0 and 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic-based human papillomavirus (HPV) DNA screening
Description: Persons randomized to arm 2 will attend a clinic where a clinician will collect the DNA specimen at 0 and 12 months.
Study: NCT01255592

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose bid
Study: NCT02025114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: The starting dose of selumetinib in combination with the standard dose of gefitinib (250mg QD) on a continuous dosing schedule will be 50mg QD. Total 3 doses of selumetinib will be tested (50mg QD, 50mg BID and 75mg BID).
Study: NCT03830645

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Application of platelet rich plasma through the intercostal tube into the pleural space
Study: NCT04497428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Sensorimotor adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Sensorimotor adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Sensorimotor adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Sensorimotor adaptation in speech

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cTBS
Description: continuous theta-burst stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cTBS
Description: continuous theta-burst stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cTBS
Description: continuous theta-burst stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cTBS
Description: continuous theta-burst stimulation
Study: NCT00830674

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose IV or SC administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN23
Description: Single IV administration on day 1: 0.003, 0.01, 0.03, 0.1 and 0.3 mg/kg and Single SC administration on day 1: 0.1, 0.3, 0.6 and 1.0 mg/kg
Study: NCT00329602

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropinirole
Description: Ropinirole IR 0.25mg/day to 4mg/day for RLS

Intervention type: DRUG
Group type: OTHER
Intervention: Ropinirole
Description: Ropinirole IR 0.25mg/day to 4mg/day for RLS
Study: NCT02133755

Intervention type: DRUG
Group type: OTHER
Intervention: Bromocriptine
Description: Three month administration of bromocriptine. Baseline ultrasound and laboratory parameters measured. Repeat measures at discontinuation of drug at 3 months.
Study: NCT03253289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meclizine Oral Tablet
Description: All subjects will receive 50 mg of meclizine taken orally, twice a day (daily dose 100 mg) for 28 (up to 35) days.
Study: NCT00581321

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water
Description: water 500 ml x 1
Study: NCT03572660

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bone marrow derived mononuclear cells and G-CSF
Description: Intra-coronary infusion
Study: NCT04172675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will receive erdafitinib orally beginning on Cycle 1 Day 1 until 2 years of treatment have been completed, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurs first. Each cycle is of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will receive erdafitinib orally beginning on Cycle 1 Day 1 until 2 years of treatment have been completed, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurs first. Each cycle is of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will receive erdafitinib orally beginning on Cycle 1 Day 1 until 2 years of treatment have been completed, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurs first. Each cycle is of 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator Choice (Gemcitabine)
Description: Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator Choice (Mitomycin C)
Description: Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.
Study: NCT03439189

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Methacetin Breath Test
Description: A breath analyzer will be used to measure changes in carbon-12 to carbon-13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Methacetin Breath Test
Description: A breath analyzer will be used to measure changes in carbon-12 to carbon-13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Methacetin Breath Test
Description: A breath analyzer will be used to measure changes in carbon-12 to carbon-13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Methacetin Breath Test
Description: A breath analyzer will be used to measure changes in carbon-12 to carbon-13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emricasan
Description: Investigational drug for NASH treatment in Main Conatus protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emricasan
Description: Investigational drug for NASH treatment in Main Conatus protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emricasan
Description: Investigational drug for NASH treatment in Main Conatus protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo versus emricasan in Conatus NASH treatment trial
Study: NCT01042509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab and rituximab
Description: Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) Rituximab at 100mg intravenously weekly for 4 doses (days 4, 11, 18 and 25
Study: NCT01388348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Urine Vibration Holter
Description: each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study
Study: NCT00336843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin-BuCyE
Description: rituximab (IV, 250 mg/m2 on days -21 and -14) single dose of 90Y-ibritumomab (IV, 0.4 mCi/kg on day -14) Busulfan (IV, 0.8 mg/kg every 6 h from day -7 to day -5) Cyclophosphamide (IV, 50 mg/kg on days -3 and -2) Etoposide (IV, 200 mg/m2 every 12 h on days -5 and -4) Autologous stem cells infusion on day 0
Study: NCT01921881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: St John's wort
Study: NCT03319511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spinal group
Description: plain bupivacaine 0.5%,1.5 ml plus dexmedetomidine 5 μg. once injection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral group
Description: plain bupivacaine 0.5%, 0.3 ml (1.5 mg)/kg plus dexmedetomidine 0.5 μg /kg divided between the T2 and T4 levels.
Study: NCT03010839

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Remote Ischemic Preconditioning
Description: mRIPC will be induced at 24 h, 12 h and 1 h before surgery and once before induction of anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control group witnout remote ischemic preconditioning
Study: NCT00998907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDS plus
Description: triclosan-coated polydiaxanon 910 suture materials with antiseptic activity (PDS plus®, Ethicon GmbH, Norderstedt, Germany)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PDS II
Description: polyglactin 910 suture material for abdominal wall closure
Study: NCT04141774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electric Stimulation (FES)
Description: FES uses low energy electrical pulses to artificially generate body movements in individuals with muscle paralysis. FES can be used to generate muscle contraction in otherwise paralyzed limbs to restore function.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Electric Stimulation (FES)
Description: FES uses low energy electrical pulses to artificially generate body movements in individuals with muscle paralysis. FES can be used to generate muscle contraction in otherwise paralyzed limbs to restore function.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Assessments
Description: These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Assessments
Description: These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: A functional magnetic resonance image will be collected.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: A functional magnetic resonance image will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG
Description: EEG electrodes will be attached to the subject's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.
Study: NCT03844022

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: magnetic resonance imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: magnetic resonance imaging
Study: NCT00682032

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-glucan
Description: AIM 2: regimen to begin after baseline blood draw; AIM 3: regimen to begin after baseline blood draw and to be completed prior to surgery

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-glucan
Description: AIM 2: regimen to begin after baseline blood draw; AIM 3: regimen to begin after baseline blood draw and to be completed prior to surgery
Study: NCT00959959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOK-001
Description: 2 capsules (325 mg each), once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOK-001
Description: 4 capsules (325 mg each), once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOK-001
Description: 6 capsules (325 mg each), once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOK-001
Description: 3 capsules (325 mg each), once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOK-001
Description: 3 capsules (325 mg each), once per day with supplement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOK-001
Description: 6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOK-001
Description: 8 capsules (325 mg each), once per day
Study: NCT03794076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cromoglycate
Description: Cromoglycate will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cromoglycate
Description: Cromoglycate will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Normal saline nasal spray will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline nasal spray will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray)
Study: NCT01451970

Intervention type: OTHER
Group type: OTHER
Intervention: High Fat Diet
Description: Subjects will adhere to their specific diet for four weeks. For both diet treatments, the diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.

Intervention type: OTHER
Group type: OTHER
Intervention: High Fat Diet
Description: Subjects will adhere to their specific diet for four weeks. For both diet treatments, the diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
Study: NCT02663102

Intervention type: OTHER
Intervention: Data collection
Description: Safety monitoring and evaluation: - Recording of all AEs during the study period using diary cards, follow-up contact via telephone or email. - Recording of SAEs throughout the study period for each subject.

Intervention type: OTHER
Intervention: Data collection
Description: Safety monitoring and evaluation: - Recording of all AEs during the study period using diary cards, follow-up contact via telephone or email. - Recording of SAEs throughout the study period for each subject.
Study: NCT00656851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 30mg/day for 16 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: Cardiorespiratory and resistance exercise training 3days/wk for 16 weeks
Study: NCT04334343

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Additional Muscle Biopsy Collection
Description: Subjects will be asked if an additional biopsy from an existing incision can be obtained (i.e. additional needle insertion). For each biopsy required in the main MoTrPAC study (NCT03960827), a small needle will be used to inject some numbing medication (similar to what a dentist uses) in your thigh. A small incision (about 1/4 inch) will be made and a special needle will be used to collect 1 or 2 muscle samples (about the size of a pea).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Additional Muscle Biopsy Collection
Description: Subjects will be asked if an additional biopsy from an existing incision can be obtained (i.e. additional needle insertion). For each biopsy required in the main MoTrPAC study (NCT03960827), a small needle will be used to inject some numbing medication (similar to what a dentist uses) in your thigh. A small incision (about 1/4 inch) will be made and a special needle will be used to collect 1 or 2 muscle samples (about the size of a pea).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Additional Muscle Biopsy Collection
Description: Subjects will be asked if an additional biopsy from an existing incision can be obtained (i.e. additional needle insertion). For each biopsy required in the main MoTrPAC study (NCT03960827), a small needle will be used to inject some numbing medication (similar to what a dentist uses) in your thigh. A small incision (about 1/4 inch) will be made and a special needle will be used to collect 1 or 2 muscle samples (about the size of a pea).